🇺🇸 US Stock Screener ← Switch market ★ Elite Club ⚡ HerAI

Option Care Health, Inc. OPCH R2K

Healthcare · Medical Care Facilities · United States
https://optioncarehealth.com
Company Profile ↓
$21.35
-30.41% 1Y
Mkt Cap$3.35B
P/E16.68
P/B2.41
52W High$36.59
52W Low$19.52
Book Value$8.61
EPS (TTM)$1.28

Company Overview

Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapy and services; home infusion services to treat heart failure; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as Duchenne muscular dystrophy, multiple sclerosis, Alzheimer's disease, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. The company is headquartered in Bannockburn, Illinois.

Why Investors Should Care

Strong Return on Equity

Generates a return on equity of 15.3%, reflecting efficient use of shareholder capital.

Consistent Profit Growth

Net profit has compounded at 25.8% per year over the last five years.

Steady Revenue Expansion

Revenue has grown at a 11.7% CAGR over the past five years.

Reasonable Valuation

Trades at a P/E of 16.7, below the sector median of 25.4.

Positive Free Cash Flow

Generates positive free cash flow, funding growth and shareholder returns internally.

Recent Developments

  • Dec 2025 Revenue of $5.65B (+13.0% YoY); net profit $207.59M.
  • Trailing 12 Months Year-on-year growth — revenue +1.3%, earnings +3.4%.
  • 5-Year Trend Long-term compounding — revenue CAGR 11.7%, profit CAGR 25.8%.

Growth & Price Performance

Compounded Sales Growth

5 Years:11.72%
1 Year:1.30%

Compounded Profit Growth

5 Years:25.84%
1 Year:3.40%

Stock Price Performance

1 Year:-30.41%
6 Months:-32.86%
3 Months:-26.20%
1 Month:+2.74%

Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.

Technical Snapshot Mixed
52-Week Range 11% of range
$19.52 $36.59
Trend Signals
  • Price vs 50-DMAAbove
  • Price vs 200-DMABelow
  • RSI (14)48.03 · Neutral
Price Performance
1M+2.74%
3M-26.20%
6M-32.86%
1Y-30.41%
Valuation vs Sector

P/E of 16.68 is below the sector median of 25.41 — relatively cheaper than peers.

Auto-generated from price history and fundamentals; not investment advice.

⚙Ad space

Price Chart

Robinhood TradingView

Fundamental Growth Charts

Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.

PROS

  • Compounding revenue at 11.7% over 5 years.
  • Profit CAGR of 25.8% over 5 years.
  • Generates positive free cash flow.

CONS

  • Trading 41.6% below its 52-week high.
  • In a downtrend (50-DMA below 200-DMA).

* The pros and cons are auto-generated from financial metrics.

⚙Ad space

Valuation

Stock P/E
16.68
Industry PE
25.41
Forward P/E
10.42
PEG Ratio
1.17
Book Value
$8.61
Price to Book
2.41
P/S
0.58
EV/EBITDA
10.84
Dividend Yield
0.00%

Growth (CAGR)

Revenue 5Y
11.72%
Profit 5Y
25.84%
Revenue (YoY)
1.30%
Earnings (YoY)
3.40%

Profitability & Returns

ROCE
12.87%
ROE
15.26%
ROA
6.19%
Profit Margin
3.64%
Op Margin
5.37%
Gross Margin
19.18%
EPS (Latest Qtr)
$0.29
EPS (TTM)
$1.28

Balance Sheet & Liquidity

Debt/Equity
0.94
Quick Ratio
1.01
Current Ratio
1.64
Debt
$1.27B
Total Assets
$3.38B
Current Assets
-
Working Capital
-

Ownership

Promoter Holding
1.20%
Chg in Prom Hold
-
FII / Inst Holding
109.79%
Chg in FII Hold
-0.35%

Financial Snapshot

Enterprise Value
$3.35B
Total Revenue (TTM)
$5.67B
EBITDA
$401.24M
Free Cash Flow
$168.69M
Operating Cash Flow
$253.55M
Shares Outstanding
157.03M
Gross Margin
19.18%
Payout Ratio
0.00%

Peer comparison

Peer companies in the same sector (Healthcare).

#NameCMP $P/E Mkt CapDiv Yld % ROCE %ROE % Rev CAGR 5Y %Profit CAGR 5Y %
1 OPCH Option Care Health, Inc. R2K 21.35 16.68 $3.35B 0.00% 12.87% 15.26% 11.72% 25.84%
2 LLY Eli Lilly and Company SPX 1,152.54 41.02 $1.03T 0.61% - 107.46% 7.20% 11.41%
3 JNJ Johnson & Johnson SPX 253.85 29.45 $611.07B 2.23% 14.88% 26.42% 2.43% 4.76%
4 ABBV AbbVie Inc. SPX 244.78 119.40 $432.48B 3.04% 10.47% -129.24% 1.75% -29.06%
5 UNH UnitedHealth Group Incorporated SPX 425.19 32.02 $386.13B 2.27% 9.74% 12.18% 10.40% 5.43%
6 MRK Merck & Co., Inc. SPX 120.78 34.02 $298.31B 2.86% - 18.94% 5.64% 10.01%
7 AZN AstraZeneca PLC NDX 164.50 24.81 $255.12B 1.77% 15.97% 23.48% 9.82% 45.96%
8 TMO Thermo Fisher Scientific Inc. SPX 534.07 29.33 $198.47B 0.40% 8.14% 13.52% 8.81% 12.95%
9 AMGN Amgen Inc. NDXSPX 355.25 24.69 $191.73B 2.84% 18.02% 101.32% 11.77% 5.58%
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios

Quarterly Results

Figures in USD.

Metric Mar 2015Jun 2015Sep 2015Dec 2015Mar 2016Jun 2016Sep 2016Dec 2016Mar 2017Jun 2017Sep 2017Dec 2017Mar 2018Jun 2018Sep 2018Dec 2018Mar 2019Jun 2019Sep 2019Dec 2019Mar 2020Jun 2020Sep 2020Dec 2020Mar 2021Jun 2021Sep 2021Mar 2022Jun 2022Sep 2022Mar 2023Jun 2023Sep 2023Mar 2024Jun 2024Sep 2024Mar 2025Jun 2025Sep 2025Mar 2026
Revenue --------217.81M218.11M198.69M182.58M460.64M479.49M493.93M505.73M476.49M497.27M615.88M720.78M705.44M740.85M781.61M804.71M759.24M860.27M891.94M915.78M980.82M1.02B1.02B1.07B1.09B1.15B1.23B1.28B-1.42B1.44B-
Gross Profit 64.95M64.82M65.23M65.91M63.30M63.27M61.72M73.79M64.87M67.61M66.56M70.19M101.70M101.27M108.25M111.00M98.19M101.39M137.77M175.64M158.03M166.32M174.15M183.76M165.47M198.97M202.97M200.94M216.90M218.00M229.00M250.83M254.27M238.50M249.37M256.75M263.05M269.04M272.90M262.01M
Operating Income -6.20M-254.00M-19.28M--1.27M-------3.06M8.90M12.76M13.55M5.44M-8.01M-11.72M13.97M8.65M23.21M34.56M44.34M29.09M48.09M52.88M52.24M59.08M60.72M66.62M82.37M81.05M69.03M80.67M85.09M79.19M82.71M84.51M72.55M
Net Income -19.67M-244.81M-16.78M-18.44M-9.83M-8.75M-11.33M-12.86M-19.72M-29.52M-12.99M-1.96M-6.85M-4.31M1.79M3.25M-3.71M-13.60M-42.79M-15.81M-19.91M-7.67M1.66M17.84M-2.86M31.82M35.48M30.27M33.93M38.82M39.21M114.40M56.30M44.79M53.04M53.86M46.74M50.52M51.82M45.34M
Diluted EPS -------------0.15-0.14---0.03-0.10-0.26-0.09-0.11-0.040.010.10-0.020.180.200.170.190.210.210.630.310.260.300.310.280.310.320.29

Profit & Loss (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Revenue 1.20B1.40B1.33B1.64B1.82B----935.59M1.83B1.94B2.31B3.03B3.44B3.87B4.30B5.00B5.65B
Gross Profit 137.01M142.17M157.82M160.54M215.41M195.90M206.65M250.75M259.95M262.08M446.00M422.21M513.00M682.26M779.61M866.92M981.22M1.01B1.09B
Operating Income 8.85M-83.52M15.47M7.54M25.55M6.68M-26.25M-97.81M-287.65M-10.99M27.28M38.27M-319.00K110.75M190.84M240.23M314.60M321.83M337.91M
Net Income 3.32M-74.03M54.10M-69.14M7.87M64.71M-69.65M-147.47M-300.13M-42.77M3.88M-6.12M-75.92M-8.08M139.90M150.56M267.09M211.82M207.59M
Diluted EPS 0.09-1.931.36-1.370.141.15-------0.49-0.040.770.831.481.231.27

Balance Sheet (Annual)

Figures in USD.

Metric Dec 2006Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Jun 2018Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Total Assets --246.96M287.22M663.99M677.10M642.38M936.86M824.71M530.64M604.99M603.09M-1.43B2.59B2.65B2.79B3.11B3.22B3.42B3.46B
Total Equity 161.83M166.20M95.54M155.79M200.10M215.28M293.41M354.58M216.59M-81.52M600.77M606.11M602.83M602.83M906.83M1.02B1.18B1.39B1.42B1.40B1.33B
Cash & Equivalents 00000062.10M1.00M740.00K15.58M9.57M39.46M-36.39M67.06M99.27M119.42M294.19M343.85M412.56M232.62M
Long Term Debt ----225.12M227.30M225.43M375.32M422.76M422.76M467.72M502.86M-535.23M1.28B1.12B1.06B1.06B1.06B1.10B1.15B
Total Liabilities --151.42M131.43M463.88M461.82M348.97M582.27M607.91M548.60M566.60M605.76M-825.39M1.68B1.63B1.62B1.73B1.80B2.02B2.13B
Current Liabilities --147.80M128.20M226.79M220.77M108.27M176.32M163.25M152.76M130.15M105.13M-240.00M330.00M434.02M459.69M565.35M618.31M780.15M829.35M

Cash Flows (Annual)

Figures in USD.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Operating Cash Flow 24.19M-8.75M22.75M-21.42M26.97M26.88M-54.58M-31.42M-64.23M-42.54M37.87M24.43M39.47M127.39M208.57M267.55M371.30M323.39M258.45M
Investing Cash Flow -5.53M-7.46M-5.74M-108.28M-9.91M93.88M-302.34M44.26M12.51M-73.21M-24.47M-37.00M-727.83M-26.33M-111.54M-108.05M-56.51M-36.47M-161.08M
Financing Cash Flow -18.66M16.21M-17.01M129.70M-17.06M-58.66M295.82M-13.10M66.56M109.74M-5.15M-4.15M719.02M-68.85M-76.87M15.27M-265.13M-218.21M-277.31M
Capital Expenditure -----------24.96M-26.28M-28.29M-26.88M-25.63M-35.36M-41.87M-35.61M-41.31M
Free Cash Flow ----------12.91M-1.85M11.18M100.52M182.94M232.19M329.43M287.79M217.14M
Share Buybacks --------------00250.26M252.73M309.95M

Ratios (Annual)

Figures in %.

Metric Dec 2007Dec 2008Dec 2009Dec 2010Dec 2011Dec 2012Dec 2013Dec 2014Dec 2015Dec 2016Dec 2017Dec 2018Dec 2019Dec 2020Dec 2021Dec 2022Dec 2023Dec 2024Dec 2025
Gross Margin % 11.4%10.1%11.9%9.8%11.8%----28.0%24.4%21.8%22.2%22.5%22.7%22.4%22.8%20.3%19.3%
Operating Margin % 0.7%-6.0%1.2%0.5%1.4%-----1.2%1.5%2.0%-0.0%3.7%5.5%6.2%7.3%6.4%6.0%
Net Margin % 0.3%-5.3%4.1%-4.2%0.4%-----4.6%0.2%-0.3%-3.3%-0.3%4.1%3.9%6.2%4.2%3.7%
ROE % 2.0%-77.5%34.7%-34.6%3.7%22.1%-19.6%-68.1%368.2%-7.1%0.6%-1.0%-8.4%-0.8%11.9%10.9%18.8%15.1%15.7%
ROCE % --84.2%9.7%1.7%5.6%1.2%-3.5%-14.8%-76.1%-2.3%5.5%3.2%-0.0%5.0%8.2%9.4%12.1%12.2%12.9%

Shareholding Pattern

Insiders
1.20%
Institutions
109.79%
Public Float
111.12%

Top Institutional Holders

#Holder% HeldSharesValue
1 Blackrock Inc. 12.67% 19.89M $428.78M
2 Wellington Management Group, LLP 7.58% 11.90M $256.51M
3 Durable Capital Partners Lp 5.73% 8.99M $193.85M
4 Vanguard Portfolio Management LLC 5.13% 8.06M $173.83M
5 Fuller & Thaler Asset Management Inc. 4.54% 7.13M $153.62M
6 Vanguard Capital Management LLC 4.47% 7.02M $151.27M
7 FMR, LLC 4.09% 6.43M $138.55M
8 State Street Corporation 3.74% 5.87M $126.66M
9 Geode Capital Management, LLC 2.71% 4.25M $91.59M
10 Arrowstreet Capital, Limited Partnership 2.70% 4.24M $91.33M

Analyst View

Loading analyst coverage…

Latest News

Recent headlines for OPCH

Google News ue, 14 Jul 2026

Y Intercept Hong Kong Ltd Sells 70,673 Shares of Option Care Health, Inc. $OPCH - MarketBeat

<a href="https://news.google.com/rss/articles/CBMi0gFBVV95cUxQTjhDcVh0YkplYk53Qlcxb0FXU3JlbHN4emViN3dlN3FCaUY2VjVrWHk2eUo3cFRlRDhoZlRNM2NnTHFPbmNJWUJIdnBDY09ySTRZSElNMnF0cnRuN2VGV0xsR1ZqN2gwck5VVVY1WE9icnNaaVdiLUN2VzdqTUlZajRoUEQ4VnBWbEFBWm…

Google News Mon, 08 Jun 2026

Billionaire Stanley Druckenmiller’s Long-Term Healthcare Stock Pick: Option Care Health (OPCH) - Yahoo Finance

<a href="https://news.google.com/rss/articles/CBMisgFBVV95cUxOaTlqNjRHNHJJZXByLS10MV9BUlZKYVdZamFmOTFJZjFQd2pUNlczNEcwclhvUWZ1VDBVcHh6SWMtR01OdV9TM2R1b2NmZW1INU5mYW9NRmxudEFZeG96SjdmTjJxb0IzcTNfSzZCMHFLSFFWckdleUxScFA5LTlTcnJDQlEwYUtpSW1faG…

Google News hu, 09 Jul 2026

Option Care Health schedules July 29 call on Q2 results - Stock Titan

<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxQb0R1cllCQWR3bVNzTl9ZVTRwM3hHcHZGNnRCOS1JWTNGZFh2bW1IdTZpVTBFYmRoZ1JrLVFBd29GaTVSMFlnUExQSUF0VnE2RUpja2xnblVoUUR0V1YyMm4tbVpLaWpuSl94eF8xdjZRQmlxWmhxMXAwV0R3ZHJMcVN0NkQydVRkejN0Rn…

Google News Fri, 26 Jun 2026

OPCH Forecast — Price Target — Prediction for 2027 - TradingView

<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE5pZUpnX3Jqck5raU9CLXVTZDVZbnBHb1FWTjVManhFbFhkRlZDRU12dU9JVFYxQmVRbXlZV2R1RThRYV82SURZTlFEMXkzWVFCUG12eXJpQjYwYUlCT1NIZlM5NGU4akdHUGV4UXVoUm1lNlZ1OE00Nlpn?oc=5" target="_blank">OPC…

Google News hu, 30 Apr 2026

Option Care Health (NASDAQ:OPCH) Misses Q1 CY2026 Revenue Estimates, Stock Drops 14.4% - StockStory

<a href="https://news.google.com/rss/articles/CBMi3wFBVV95cUxPRlgzY3hiVXJHQWc1OVR6LU5NaVY0S083b1Ixd0k1YVA0N1RlNkU3czYwWjN3UmxuWU9nSDhMWHJwdnpKWldWY0I2V3c1VWlTMTd0VmxQWW5YQTdIZWVjTERvNThYLUtYOEd0a1lmdGpEcjNKU3N1V0ctVnJDOC1UX25vVFJRc2RxZEJ6bU…

Google News Wed, 27 May 2026

OPCH - Option Care Health Inc Stock Price and Quote - Finviz

<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE5mRl9RVU1MY1cyTXEzMWYzVEJmTVJtS0lFaHZhb041QkdHX2twUG5YTW5XZ3lmWjh5aHJ0UFVqWWxLMDF4Smc?oc=5" target="_blank">OPCH - Option Care Health Inc Stock Price and Quote</a>&nbsp;&nbsp;<font…

OPCH — Frequently Asked Questions

What is the current share price of Option Care Health, Inc. (OPCH)?

As of 2026-07-14 21:23 PDT, Option Care Health, Inc. (OPCH) trades at $21.35 on NasdaqGS. Its 52-week range is $19.52 to $36.59.

What is the market capitalisation of OPCH?

Option Care Health, Inc. (OPCH) has a market capitalisation of $3.35B on NasdaqGS.

What is the P/E ratio of OPCH?

OPCH trades at a trailing price-to-earnings (P/E) ratio of 16.68. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 2.41.

What is the return on equity (ROE) of OPCH?

OPCH has a return on equity (ROE) of 15.26%. Its return on capital employed (ROCE) is 12.87%.

Is OPCH a good stock to buy?

This page provides a data-driven analysis of Option Care Health, Inc. (OPCH), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.

Explore More

📊 Healthcare Sector 🔍 All Stock Screens 📈 Technical Screens 💰 Fundamental Screens 🔄 Swing Trading Setups 📐 Chart Patterns 📅 Earnings Calendar 📋 All USA Stocks
⚙Ad space